TY - JOUR
T1 - Emerging Insights and Interventions for Diabetic Retinopathy
AU - Honasoge, Avinash
AU - Nudleman, Eric
AU - Smith, Morton
AU - Rajagopal, Rithwick
N1 - Funding Information:
Eric Nudleman reports grants from the National Eye Institute (5K08EY028999-02). Rithwick Rajagopal reports grants from the National Eye Institute (K08EY025269) and grants from the Research to Prevent Blindness (Career Development Award).
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Purpose of Review: To introduce recent advances in the understanding of diabetic retinopathy and to summarize current and emerging strategies to treat this common and complex cause of vision loss. Recent Findings: Advances in retinal imaging and functional analysis indicate that retinal vascular and neural pathologies exist long before the development of clinically visible retinopathy. Such diagnostics could facilitate risk stratification and selective early intervention in high-risk patients. Antagonists of the vascular endothelial growth factor pathway effectively reduce vision loss in diabetes and promote regression of disease severity. Promising new strategies to treat diabetic retinopathy involve novel systemic diabetes therapy and ocular therapies that antagonize angiogenic growth factor signaling, improve blood-retina barrier function and neurovascular coupling, modulate neuroretinal metabolism, or provide neuroprotection. Summary: Long considered a pure microvasculopathy, diabetic retinopathy in fact affects the neural and vascular retina as well as neurovascular communication. Emerging therapies include those that target neuroretinal dysfunction in addition to those modulating vascular biology.
AB - Purpose of Review: To introduce recent advances in the understanding of diabetic retinopathy and to summarize current and emerging strategies to treat this common and complex cause of vision loss. Recent Findings: Advances in retinal imaging and functional analysis indicate that retinal vascular and neural pathologies exist long before the development of clinically visible retinopathy. Such diagnostics could facilitate risk stratification and selective early intervention in high-risk patients. Antagonists of the vascular endothelial growth factor pathway effectively reduce vision loss in diabetes and promote regression of disease severity. Promising new strategies to treat diabetic retinopathy involve novel systemic diabetes therapy and ocular therapies that antagonize angiogenic growth factor signaling, improve blood-retina barrier function and neurovascular coupling, modulate neuroretinal metabolism, or provide neuroprotection. Summary: Long considered a pure microvasculopathy, diabetic retinopathy in fact affects the neural and vascular retina as well as neurovascular communication. Emerging therapies include those that target neuroretinal dysfunction in addition to those modulating vascular biology.
KW - Diabetic macular edema
KW - Diabetic retinopathy
KW - Neuroretinopathy
KW - Neurovascular coupling
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=85072034513&partnerID=8YFLogxK
U2 - 10.1007/s11892-019-1218-2
DO - 10.1007/s11892-019-1218-2
M3 - Review article
C2 - 31506830
AN - SCOPUS:85072034513
SN - 1534-4827
VL - 19
JO - Current Diabetes Reports
JF - Current Diabetes Reports
IS - 10
M1 - 100
ER -